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Abstract A monoclonal antibody (AP422) specific for phos- 
pboserine 422 in microtubnle-associated protein tau has been 
produced. It strongly labels paired helical f'dament (PHF) tan 
from Alzheimer's disease brain in a pbosphorylation-dependent 
manner. By contrast, AP422 only labels a small fraction of fetal 
tau and a very small fraction of tan from adult brain. The amount 
of tau phospborylated at Ser-422 in normal brain is minor 
relative to that phosphorylated at sites recognized by other 
pbosphorylation-dependent a i-tau antibodies of known epitope. 
It follows that AP422 is the most specific anti-tau antibody 
available for detecting the neurofibrillary lesions of Alzheimer's 
disease. We also show that Ser-422 in tau is a good in vitro 
substrate for mitogen-activated protein kinase, but not for 
glycogen synthase kinase-3 or neuronal cdc2-1ike kinase. 
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1. Introduction 
Abundant neurofibrillary lesions made of paired helical fi- 
laments (PHFs) constitute one of the major neuropathological 
hallmarks of Alzheimer's disease (AD). Hyperphosphorylated 
microtubule-associated protein tau (PHF-tau) is the major 
component of the PHF (for reviews, see Refs. [1-3]). Exten- 
sive protein chemical and immunochemical studies have iden- 
tified about 20 hyperphosphorylated amino acids in PHF-tau, 
almost all of which flank the microtubule-binding repeats [4- 
8]. Approximately half of these sites are serine/threonine-pro- 
lines [8]. Phosphorylation atmany of these sites is also present 
in a significant fraction of fetal tau [7,9,10] and studies using 
biopsy-derived tau have shown that they are also phosphory- 
lated in a small fraction of tau from adult human brain [11]. 
The hyperphosphorylation f tau could result from an in- 
creased activity of a tau kinase or the decreased activity of 
a tau phosphatase. Based on in vitro experiments mitogen- 
activated protein (MAP) kinase [12], neuronal cdc2-1ike kinase 
(NCLK) [13,14] and glycogen synthase kinase-3 (GSK3) 
[15,16] are candidate protein kinases for the hyperphosphor- 
ylation of tau, whereas protein phosphatase 2A [17,18] is a 
candidate phosphatase. It has recently been shown that sig- 
nificant proportions of MAP kinase [19] and phosphatase 2A 
[20] are associated with microtubules in cultured cells. How- 
ever, it is not clear which protein kinases and protein phos- 
phatases act on tau in normal and AD brain. 
In order to investigate the hyperphosphorylation of PHF- 
tau further, we have produced and characterized a monoclo- 
nal antibody (AP422) directed against phosphoserine 422 in 
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tau (using the nomenclature of the longest human brain tau 
isoform). We show here that AP422 strongly recognizes PHF- 
tau; it also recognizes a small fraction of fetal human tau and 
biopsy-derived adult human tau, as well as a small fraction of 
fetal and adult rat tau. However, the amount of tau phos- 
phorylated at Ser-422 in normal brain is very small relative 
to that phosphorylated at sites recognized by other phosphor- 
ylation-dependent anti-tau antibodies. We also show that Ser- 
422 is a good substrate for MAP kinase, but not for NCLK 
and GSK3. 
2. Materials and methods 
2.1. Antibodies 
Monoclonal antibody (mAb) AP422 was raised against a synthetic 
phosphopeptide, CGGIDMVDS(P)PQLAT, where S(P) represents 
phosphoserine. 50 Ixg of peptide was injected into the footpads of 
BALB/c mice, which were boosted with another 50 I.tg of peptide on 
days 4, 7, and 12. On day 14 the regional lymph nodes were removed 
and the cells fused with myeloma cells (line PAI) using polyethylene 
glycol 4000. Screening of positive clones was done by enzyme-linked 
immunosorbent assay. Ascites was prepared by intraperitoneal injec- 
tion of cloned hybridoma cells and used in all experiments. The pro- 
duction of an antiserum against phosphoserine 422 (AS AP422) has 
been described previously [8]. BR134 recognizes the carboxy-terminus 
of tan [21], whereas AT8, C5 and M4 are previously described phos- 
phorylation-dependent anti-tau antibodies [7,22,23]. Antibodies were 
diluted as follows: 134 (1:2500), mAb AP422 (1:2000), M4 (1:3000), 
C5 (1:2000) for immunoblotting of site-directed mutants; 134 
(1:3000), AT8 (1:2000), mAb AP422 (1:3000) for immunoblotting 
of Sarkosyl-PHFs and dephosphorylated PHF-tau; 134 (1:5000), 
AT8 (1:2000), mAb AP422 (1:2000) for immunoblotting of human 
and rat tau; 134 (1:5000), AT8 (1:2000), mAb AP422 (1:5000) for 
immunoblotting of htau40 phosphorylated byMAP kinase, NCLK or 
GSK3. 
2.2. Preparation of recombinant tau and phosphorylation 
A full-length cDNA clone encoding the 383 amino acid isoform of 
human tau (htau24) [21] was used to mutate codons 202 (Ser to Ala; 
$202A), 231 (Thr to Ala; T231A), 235 (Ser to Ala; $235A), 396 (Ser 
to Ala; $396A), 404 (Ser to Ala; $404A) and 422 (Ser to Ala; $422A). 
Wild-type and mutated tau proteins were expressed and purified as 
described [24]. Phosphorylation of recombinant tau with activated 
recombinant p42 MAP kinase [24], reconstituted recombinant 
NCLK [25] and GSK3 ~ and I] purified from rabbit skeletal muscle 
[26] were carried out as described, in the presence or absence of 100 
~tg/ml heparin [18,23]. Phosphorylation f recombinant tan by total 
rat brain protein kinase activity was carried out as described [24]. 
2.3. Extraction of tau protein and immunoblotting 
Tau proteins were extracted from brains of 1-day-old and 10-week- 
old rats and immunoblotted, as described [24]. The brains were homo- 
genized in 2.5% perchloric acid within 1 min after death, so as to 
prevent he action of phosphatases on tan. Tau from a fetal human 
brain (21 weeks of gestation) and biopsy-derived a ult human brain 
tau were prepared as described [11]. PHF-tau was prepared from a 
Down's syndrome brain according to Greenberg and Davies [27], with 
minor modifications. The Sarkosyl-insoluble p llets were resuspended 
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in 6 ml 50 mM Tris-HC1, pH 7.4, and re-centrifuged. The pellets were 
resuspended in 50 mM Tris-HC1 (250/.tl per g starting material, Sar- 
kosyl-PHF1), or in 50 mM Tris-HC1 containing 7 M guanidine-HC1 
and 2% 13-mercaptoethanol. Guanidine-HC1 solubilized PHF-tau was 
dialyzed overnight at 4°C against 20 mM Tris-HC1, pH 7.4, and 
centrifuged for 10 min at 346000xg. The resulting supernatant was 
used (Sarkosyl-PHF2). Prior to alkaline phosphatase treatment Sar- 
kosyl-insoluble p llets and guanidine-HC1 solubilized PHF-tau were 
dialyzed against 50 mM Tris-HC1, pH 8.0, containing 1mM PMSF 
and 0.1 mM EDTA. E. coli alkaline phosphatase (13.5 U/ml; type III- 
N, Sigma) and 1 mM MgC12 were added and incubations carried out 
at 67°C for 2 h. 
2.4. Immunohistochemistry and immunoelectron microscopy 
Occipito-temporal cortex from an AD brain was fixed in phos- 
phate-buffered 4%paraformaldehyde for 24 h at 4°C. Vibratome sec- 
tions (50 ~tm) were immunostained with mAb AP422 at a dilution of 
1 : 1000 in PBS containing 10% fetal calf serum and developed using 
avidin-biotin (Vectastain). Immunolabelling of dispersed PHFs ex- 
tracted from AD brain with mAb AP422 was carried out as described 
[7]. MAb AP422 was used at a dilution of 1:1000 in PBS containing 
10% fetal calf serum. Filaments were dephosphorylated by treatment 
with E. coli alkaline phosphatase (27 U/ml; type III-N, Sigma) for 
various times at 67°C. Micrographs were recorded on a Philips 
EM301, at an operating voltage of 80 kV and at a nominal magnifica- 
tion of x 25 000. 
3. Results 
3.1. Antibody specificities 
For epitope mapping of tau antibodies we used htau24 to 
prepare wild-type recombinant tau, $202A tau, T231A tau, 
$235A tau, $396A tau, $404A tau and $422A tau. Phosphor- 
ylation with brain extract resulted in a marked reduction in 
the gel mobility of recombinant tau. MAb AP422 failed to 
recognize wild-type or mutated recombinant tau prior to 
phosphorylation (Fig. 1). However, following an overnight 
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incubation with brain extract, mAb AP422 recognized wild- 
type tau and all mutated tau proteins, with the exception of 
phosphorylated $422A tau (Fig. 1). Immunoblotting with AS 
AP422 gave similar results; however, weak staining was de- 
tected with non-phosphorylated wild-type tau, when a large 
amount of tau was loaded, suggesting that this antiserum ay 
not be entirely phosphorylation-dependent. By comparison, 
monoclonal ntibodies M4 and C5, which were raised against 
PHF-tau, showed different patterns. M4 stained phosphory- 
lated wild-type tau, $202A tau, $396A tau, $404A tau and 
$422A tau, but failed to stain T231A tau (Fig. 1). M4 also 
hardly recognized phosphorylated $235A tau, indicating that 
it is specific for phosphorylated Thr-231 and Ser-235. C5 
stained phosphorylated wild-type tau and mutated tau pro- 
teins, with the exception of $396A tau (Fig. 1), indicating 
that it is specific for phosphorylated Ser-396. 
3.2. Immunoreactivity of PHF-tau, human brain tau and rat 
brain tau with mAb AP422 
MAb AP422 strongly labelled PHF-tau in either the Sarko- 
syl-PHF1 or the cleaner Sarkosyl-PHF2 fraction (Fig. 2). The 
staining intensity was similar to that given by antibody 134 
and the phosphorylation-dependent anti-tau antibody, AT8 
(Figs. 2 and 3). Sarkosyl-insoluble PHFs and guanidine-HC1 
solubilized PHF-tau were dephosphorylated by alkaline phos- 
phatase and immunoblotted with 134, AT8 and mAb AP422. 
Alkaline phosphatase treatment of intact PHFs resulted in 
marked changes in the electrophoretic mobility of PHF-tau 
and the loss of AT8 immunoreactivity (Fig. 2). By contrast, 
mAb AP422 immunoreactivity was only reduced. Similar re- 
suits were obtained with PHF1 which recognizes phosphory- 
lated serines 396 and 404 (data not shown). However, alkaline 
phosphatase treatment of guanidine-HC1 solubilized PHF-tau 
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Fig. 1. Phosphorylation f wild-type and mutated recombinant tau proteins (htau24) with rat brain extract. Immunoblots were stained with 
anti-tau serum 134 and phosphorylation-dependent mo oclonal nti-tau antibodies AP422, M4 and C5. Lanes: 1, htau24; 2, htau24+ brain ex- 
tract; 3, T231A htau24+brain extract; 4, $235A htau24+ brain extract; 5, $396A htau24+brain extract; 6, $404A htau24+ brain extract; 7, 
$422A htau24+brain extract. 
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Fig. 2. Immunoblots of Sarkosyl-PHFs and dephosphorylated PHF- 
tau with anti-tau serum 134 and phosphorylation-dependent mo o- 
clonal anti-tau antibodies AT8 and AP422. Lanes: 1, Sarkosyl- 
PHFs; 2, Sarkosyl-PHFs incubated with alkaline phosphatase; 
3, guanidine-treated PHFs; 4, guanidine-treated PHFs incubated 
with alkaline phosphatase. 
resulted in the removal of mAb AP422 immunoreactivity 
(Fig. 2). 
We next examined whether the phosphorylation of Ser-422 
can be detected in fetal human tau and in biopsy-derived 
adult human tau. MAb AP422 only faintly stained human 
fetal tau which by comparison was strongly labelled by AT8 
(Fig. 3). When the same amount of biopsy-derived adult hu- 
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man tau (2 ~g) as that of fetal tau was immunoblotted, no 
immunoreactivity could be detected with mAb AP422, while 
AT8 showed significant staining (data not shown). When the 
amount of biopsy-derived tau was increased 6-fold (12 I.tg), 
very weak staining could be detected with mAb AP422 
(Fig. 3). This faint staining cannot be explained by a low 
antibody titre, since PHF-tau was labelled equally strongly 
by mAb AP422 and AT8, while the converse was true of 
biopsy-derived adult human tau (Figs. 2 and 3). Similar to 
tau from human brain, a fraction of fetal rat tau was stained 
by mAb AP422, whereas tau from adult rat brain was only 
stained very weakly (Fig. 3). Tau was the only protein recog- 
nized by mAb AP422 in a crude extract from newborn rat 
brain. 
3.3. Immunostaining with mAb AP422 
Vibratome sections from AD cerebral cortex were stained 
with either mAb AP422 or AS AP422. Both antibodies 
strongly labelled intracellular neurofibrillary tangles, neuropil 
threads and plaque neurites (Fig. 4). By immunoelectron mi- 
croscopy mAb AP422 strongly decorated a majority of dis- 
persed PHFs (Fig. 5a), similar to the labelling with antibody 
134. Alkaline phosphatase treatment of PHFs at 67°C for 2 h 
failed to remove the labelling with mAb AP422. However, 
when alkaline phosphatase was added twice over a 24 h per- 
iod at 67°C, the labelling was abolished (Fig. 5b). 
3.4. Immunoreactivity of tau following phosphorylation with 
MAP kinase, GSK3 and NCLK 
The 441 amino acid isoform of human brain tau was phos- 
phorylated with MAP kinase, NCLK or GSK3 tx and [3, in 
the presence or absence of 100 p.g/ml heparin, a known acti- 
vator of tau phosphorylation with a number of protein ki- 
nases [28-30]. In the presence of heparin recombinant tau 
incubated with p42 MAP kinase incorporated 8 mol phos- 
phate/mol of protein; tau incubated with GSK3[3 and heparin 
incorporated 10 tool phosphate/mol protein, whereas tau in- 
cubated with NCLK and heparin incorporated 12 mol phos- 
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Fig. 3. Immunoblots of PHF-tau, fetal tau and biopsy-derived adult tau with anti-tau serum 134 and phosphorylation-dependent mo oclonal 
anti-tau antibodies AT8 and AP422. Total protein loaded is indicated in brackets. Lanes: 1, fetal rat tau (2 ~tg); 2, fetal human tau (2 p.g); 
3, adult rat tau (2 ~tg); 4, biopsy-derived adult human tau (12 p.g); 5, PHF-tau (Sarkosyl-PHF2) (1.5 ~g). 
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Fig. 4. AD cortex immunostained with mAb AP422. Note the stain- 
ing of numerous neurofibrillary tangles, neuropil threads and plaque 
neurites. Magnification, × 400. 
phate/mol protein. Phosphorylation with NCLK or GSK3 in 
the presence of heparin resulted in a dramatic shift in the gel 
mobility of tau and generated the AT8 epitope, but not the 
epitope of mAb AP422 (Fig. 6). Phosphorylation by MAP 
kinase with or without heparin also resulted in a marked re- 
duction in the gel mobility of tau and generated not only the 
AT8 epitope, but also the epitope of mAb AP422 (Fig. 6). 
Weak staining of tau phosphorylated by NCLK in the pres- 
ence of heparin could be detected with mAb AP422 when a 
large amount of phosphorylated tau was immunoblotted ( ata 
not shown). 
4. Discussion 
By using a combination of site-directed mutagenesis and in 
vitro phosphorylation we have shown that mAb AP422 is 
specific for tau phosphorylated at Ser-422. AP422 strongly 
recognized PHF-tau on immunoblots and decorated PHFs 
by electron microscopy, in agreement with previous mass 
spectrometric results demonstrating the presence of phospho- 
serine 422 in PHF-tau [8]. By contrast, AP422 recognized fetal 
human and rat tau only weakly. Similarly, biopsy-derived 
adult human tau and adult rat tau gave only a very weak 
signal when immunoblotted with AP422. These results show 
that mAb AP422 gives a staining pattern that is qualitatively 
similar to that given by other phosphorylation-dependent 
anti-tau antibodies of known epitope (antibodies AT8, 
AT180, M4, AT270, 12E8, PHF1 and C5)[7,11,22-24,31]. 
All these antibodies recognize PHF-tau more strongly than 
fetal tau which is in turn labelled more strongly than adult 
tau. However, there are important quantitative differences in 
that AP422 recognized a much smaller fraction of fetal and 
adult tau than the other antibodies. This was especially true of 
biopsy-derived adult human tau which was hardly recognized 
by mAb AP422. Thus, AP422 is almost entirely specific for 
PHF-tau and is presently the most specific such antibody of 
known epitope available. The low levels of phosphorylation 
probably explain previous failures to detect phosphorylation 
at Ser-422 in fetal and adult rat tau by mass spectrometry or
by immunoblotting with AS AP422 [8]. It follows that in tau 
from normal brain Thr-181, Ser-202, Thr-205, Thr-231, Ser- 
235, Ser-262, Ser-396 and Ser-404 are phosphorylated to a 
greater extent han Ser-422, whereas imilar proportions are 
phosphorylated at each site in PHF-tau. These results indicate 
that in tau from normal brain different sites are phosphory- 
lated to different extents. Dephosphorylation experiments 
showed that mAb AP422 recognizes PHFs and PHF-tau in 
a phosphorylation-dependent manner. They also demon- 
strated that phosphorylated Ser-396, Ser-404 and Ser-422 in 
tau from PHFs are much more resistant to alkaline phospha- 
tase than are phosphorylated Ser-202 and Thr-205. 
Many of the phosphorylation sites in tau are serine/threo- 
!ii~ I i~, 
Fig. 5. Immunoelectron microscopy of dispersed PHFs with mAb AP422. (a) Native material; (b) PHFs treated with alkaline phosphatase b - 
fore immuno-decoration. Note immuno-decoration f filaments in (a). Scale bar, 200 nm. 
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Fig. 6. Phosphorylation f the 441 amino acid isoform of human tau (htau40) with NCLK, GSK3 and MAP kinase in the presence or absence 
of heparin. Immunoblots were stained with anti-tau serum 134 and phosphorylation-dependent mo oclonal anti-tau antibodies AT8 and 
AP422. Lanes: 1, htau40; 2, htau40+NCLK; 3, htau40+NCLK+heparin; 4, htau40+GSK3[3; 5, htau40+GSK3~+heparin; 6, htau40+MAP ki- 
nase; 7, htau40+MAP kinase+heparin. 
nine-prolines which can be phosphorylated in vitro by proline- 
directed protein kinases, such as MAP kinase, NCLK and 
GSK3. Of these only MAP kinase phosphorylated recombi- 
nant tau at Ser-422, as demonstrated by the generation of the 
AP422 epitope. GSK3 failed to phosphorylate Ser-422, even 
in the presence of heparin, a known activator of tau phos- 
phorylation by a number of protein kinases [28-30]. Phos- 
phorylation of recombinant tau by NCLK resulted in very 
weak labelling with AP422 when a large amount of phos- 
phorylated tau was loaded. These results indicate that MAP 
kinase or a MAP kinase-like nzyme may be involved in the 
phosphorylation f PHF-tau. It is unknown whether hyper- 
phosphorylation f tau in the AD brain results from an in- 
creased protein kinase activity, a decreased protein phospha- 
tase activity, or a combination of both. It is also not known 
whether hyperphosphorylation of tau precedes PHF forma- 
tion nor whether it is either necessary or sufficient for PHF 
formation. However, it is clear that the inability of PHF-tau 
to bind to microtubules i  the direct result of its hyperphos- 
phorylation [32,33]. Moreover, immunohistochemical studies 
on transentorhinal cortex have indicated that hyperphosphor- 
ylation of tau may precede PHF formation [34]. Current evi- 
dence on phosphorylation f tau by known protein kinases 
indicates that multiple nzymes are likely to be involved in the 
hyperphosphorylation of tau. One challenge for the future is 
to evaluate the contributions made by phosphorylation at in- 
dividual sites to the pathological behaviour of tau in the AD 
brain. MAb AP422 will be a valuable reagent in this under- 
taking. 
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